Background A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC
are shown to be frail by a comprehensive geriatric assessment. This population is more …

Background The median age of newly diagnosed patients with non-small cell lung cancer
(NSCLC) is 67 years, and one-third of patients are older than 75 years. Elderly patients are …

Purpose National Cancer Institute of Canada Clinical Trials Group Study BR. 21 established
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …

Background In this prospective non-interventional study, the effectiveness and tolerability of
erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after≥ 1 platinum …

The incidence and mortality of lung cancer have increased worldwide over the last decades,
with an observed increased incidence particularly among elderly populations. It has not yet …

19016 Background: The prognosis for elderly pts with advanced NSCLC is generally poor
due to significant co-morbidities that limit treatment options. Furthermore, aggressive …

Lung cancer in the older individual is an increasingly common problem faced by the
oncologist. Elderly patients over 70years account about 40% of lung cancer patients …

7168 Background: Elderly patients derive survival benefit but significant toxicity from
chemotherapy for NSCLC. Erlotinib is associated with reasonable toxicity and has a survival …

Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has
been historically undertreated for various reasons such as perceived frailty and comorbidity …

In order to evaluate the clinical efficacy and the safety profile of molecularly targeted
therapies as a palliative approach in elderly populations affected by advanced thoracic …